Em Portugal, onde o cancro da cabeça e pescoço afeta cerca de três mil pessoas por ano, cinco hospitais vão começar a recrutar doentes para um ensaio clínico de uma imunoterapia experimental chamada amivantamab. Desenvolvida pela Johnson & Johnson, a substância não combate o tumor com veneno, mas com persuasão — ensinando o sistema imunitário a reconhecer e atacar as células cancerígenas. Os primeiros resultados, apresentados a oncologistas de todo o mundo, sugerem que esta abordagem pode abrir uma porta para doentes cujas opções já se esgotaram.
Jornal SOL
· Jun 03, 2026
· health
· 1 min read
High
Sourcing: Verified
Portugal to test promising immunotherapy injection for head and neck cancer
The trial involves patients with recurrent or metastatic head and neck cancers, forms that are particularly difficult to treat and carry significant health burden.
◉
Health & Medicine
2697 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% match
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% match
Related Coverage
Folha de S.Paulo · Aug 18
Cisne mantém reinado como melhor sal entre paulistanos pela quinta vez
A marca Cisne vence pela quinta vez consecutiva a pesquisa Datafolha como melhor sal entre paulistanos, com 50% das menç…
Folha de S.Paulo · Aug 18 Projeto Quebrada Alimentada é eleito iniciativa de destaque em gastronomia pela FolhaO projeto Quebrada Alimentada, nascido no restaurante Mocotó durante a pandemia, foi eleito iniciativa de destaque pela …
UOL · Aug 17 Lucy Ramos revela que Globo consultou obstetra para cena de acidente na novelaA atriz Lucy Ramos revelou que a Globo consultou seu obstetra antes de gravar uma cena de acidente fatal enquanto ela es…
Estadão · Aug 17 Asma não impede atividade física; exercício regular ajuda no controle da doençaPesquisas confirmam que atividade física beneficia asmáticos, mas requer controle da doença e atenção a fatores ambienta…
Bias & Framing
⚖
Article presents clinical trial information with optimistic framing of early results; minimal bias detected, though emphasis on positive outcomes without proportional discussion of limitations.
Bias Direction
center
Confidence
MED
Positive framing emphasizing promising results and hope; uses encouraging language ('promissores', 'encorajadores') while presenting clinical data. Frames Portugal's participation as significant advancement without critical context.
promissores (promising)
encorajadores (encouraging)
novidade (novelty/exciting news)
desaparecimento completo (complete disappearance)
estratégia inovadora (innovative strategy)
Potential side effects or adverse reactions from the treatment
Comparative efficacy data against existing treatments
Expert skepticism or cautionary perspectives from oncologists
Cost and accessibility considerations
Realistic timeline expectations for patient access
Failure rates or non-responder characteristics
Patient or caregiver testimonials about concerns
Geopolitical Impact
🌎
Portugal joins international clinical trials for Johnson & Johnson's amivantamab immunotherapy, a medical advancement with minimal geopolitical implications but reflecting Western pharmaceutical leadership.
Escalation Risk
low
Confidence
HIGH
Portugal
United States
European Union
Reinforces U.S. pharmaceutical dominance through Johnson & Johnson's global trial network; strengthens Portugal's position within EU healthcare innovation ecosystem; demonstrates continued Western biotech leadership in cancer treatment.
Economic Lens
📈
Portugal joins clinical trials for Johnson & Johnson's amivantamab immunotherapy for head/neck cancer, with >33% positive response rates, signaling growth in oncology biotech and healthcare innovation sectors.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical & Biotechnology
Healthcare & Medical Services
Hospital & Clinical Services
Medical Research & Development
Patients with recurrent/metastatic head and neck cancer gain access to promising experimental treatment with potential for tumor reduction or remission. Expands treatment options for difficult-to-treat cancers, potentially improving health outcomes and quality of life for affected individuals.
Positive regulatory signal for accelerated drug approval pathways in Portugal/EU. May incentivize increased healthcare R&D investment and clinical trial infrastructure. Potential for future reimbursement discussions with national health systems if efficacy confirmed. Strengthens Portugal's position in European biomedical research.